Monoclonal antibody directed against an epitope of p53 within residue 88-93.
| Inventor | Institute |
|---|---|
| David Lane | Cancer Research UK, London Research Institute: Clare Hall Laboratories |
| Cat. #: | 151412 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Cancer types: | Other |
| Research Fields: | Apoptosis and autophagy;Cancer;Cell biology;Genetics |
| Application: | IHC ; IP |
| Target: | p53 mouse, wild type only |
| Reactivity: | Mouse |
| Clone: | Pab 246 |
| Host: | Mouse |
| Class: | Monoclonal |
| Primary citation: | Yewdell et al. 1986. J Virol. 59(2):444-52. PMID: 2426467. |
| Product description: | Anti-p53 clone Pab 246 recognises the tumour antigen p53, also known as p53 tumour suppressor protein or NY-CO-13. p53 is upregulated in response to DNA damage and is found in a wide variety of transformed cells. Mutations in p53 can lead to conformational changes in the protein, exposing different epitopes. Pab 246 binds to the wild-type conformation of p53 |
|---|---|
| Conjugation: | Unconjugated |
| Isotype: | IgG1 kappa |
| Molecular weight: | 50 kDa |
| Immunogen: | SV40-transformed cell line Balb/c SVA31 E7. |
| Immunogen Uniprot ID: | P02340 |
| Myeloma used: | Sp2/0-Ag14 |
| Target background: | p53 is a crucial tumour suppressor involved in over 50% of cancers. It acts as a stress-responsive transcription factor and plays a vital role in regulating cell cycle arrest, promoting apoptosis, maintaining genomic stability, controlling the cell cycle, and inhibiting angiogenesis. Known as the "guardian of the genome," p53 prevents gene mutations. Mutations in the p53 gene are common in human cancers, resulting in dysfunctional proteins unable to bind to DNA. This loss of fun… |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | Store at -20° C frozen. Avoid repeated freeze / thaw cycles |
| Shipping conditions: | Dry ice |
| References: |
Pradhan et al. 2019. Nucleic Acids Res. 47(4):1637-1652. PMID: 30649466. Hwang et al. 2018. Cell Rep. 22(1):299-312. PMID: 29298430. Labalette et al. 2008. PLoS One. 3(11):e3761. PMID: 19018287. Han et al. 2008. Cell Stem Cell. 2(3):241-51. PMID: 18371449. Gannon et al. 1990. EMBO J. 9(5):1595-602. PMID: 1691710. Yewdell et al. 1986. J Virol. 59(2):444-52. PMID: 2426467. Wade-Evans et al. 1985. EMBO J. 4(3):699-706. PMID: 2408882. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151015 | Anti-CyclinA [E70.1] |
Key Info
Anti-CyclinA [E70.1]
|
View Tool | |||||||||||||||||||
| 151021 | Anti-CyclinB1 [V152] |
Key Info
Anti-CyclinB1 [V152]
|
View Tool | |||||||||||||||||||
| 151028 | Anti-Cytochrome P450 2C2, 2B1/2 [h7] |
Key Info
Anti-Cytochrome P450 2C2, 2B1/2 [h7]
|
View Tool | |||||||||||||||||||
| 151036 | Anti-ICAM1 [15.2] |
Key Info
Anti-ICAM1 [15.2]
|
View Tool | |||||||||||||||||||
| 151018 | Anti-Mos [R38.1] |
Key Info
Anti-Mos [R38.1]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.